Adjunctive therapy, to diet to reduce elevated total-C, LDL-C, Apo B, non HDL-C & triglycerides & to increase HDL-C in adults w/ primary hyperlipidemia or mixed dyslipidemia; to reduce total-C, LDL-C & Apo B in adolescent boys & girls, who are at least 1 yr post-menarche, 10-17 yr w/ heterozygous familial hypercholesterolemia & +ve family history of premature CV disease or ≥2 other CV disease risk factors; patients w/ hypertriglyceridemia; primary dysbetalipoproteinemia (type III hyperlipoproteinemia); other lipid-lowering treatments (eg, LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, total-C & Apo B in adult patients w/ homozygous familial hypercholesterolemia; to slow the progression of atherosclerosis in adults, as part of a treatment strategy to lower total-C & LDL-C. Reduce risk of stroke, MI & arterial revascularization procedures.
Sign Out
